It is made available under a CC-BY-NC 4.0 International license .

1 Exploration of wastewater surveillance for Monkeypox virus

- 2
- 3 Edgard M Mejia^{1,#}, Nikho A Hizon^{1,#}, Codey E Dueck¹, Ravinder Lidder¹, Jade Daigle¹, Quinn
- 4 Wonitowy¹, Nestor G Medina¹, Umar P Mohammed¹, Graham W Cox¹, David Safronetz^{2,4},
- 5 Mable Hagan², Jim Strong^{2,4}, Anil Nichani¹, Michael R Mulvey^{1,3,4} and Chand S Mangat^{1,3,4*}
- 6
- ¹Wastewater Surveillance Unit, One Health Division, National Microbiology Laboratory, Public
 Health Agency of Canada, Winnipeg, Canada
- 9 ²Special Pathogens Section, National Microbiology Laboratory, Public Health Agency of
- 10 Canada, Winnipeg, Canada
- ¹¹ ³Antimicrobial Resistance Nosocomial Infections, National Microbiology Laboratory, Public
- 12 Health Agency of Canada, Winnipeg, Canada
- 13 ⁴Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine,
- 14 Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada
- 15
- 16 *Corresponding Author: Chand S. Mangat, One Health Division, National Microbiology
- 17 Laboratory, Public Health Agency of Canada.
- 18 #These authors contributed equally to this work.
- 19 Address: JC Wilt Infectious Diseases Research Centre
- 20 745 Logan Ave
- 21 Winnipeg, MB, Canada
- 22 R3E 3L5
- 23 Email: chand.mangat@phac-aspc.gc.ca, Tel: 204-789-6506, Fax: 204-789-5020
- 24 Key words: Monkeypox, wastewater, real-time qPCR
- 25 Running title: Detection of Monkeypox in Canadian wastewater
- 26
- 27
- 28
- 29

It is made available under a CC-BY-NC 4.0 International license .

30 Abstract

31

The sudden emergence and spread of Monkeypox in non-endemic parts of the 32 world is currently not well understood. Infections are often mis-diagnosed and 33 surveillance strategies are scarce. Wastewater-based surveillance (WBS) of human 34 Monkeypox virus (MPXV) can help supplement our current clinical surveillance and 35 mitigation efforts. WBS has shown to be an effective tool in monitoring the spread of 36 other infectious pathogens, such as SARS-CoV-2 and its variants, and has helped 37 guide public health actions. In this study, we describe how WBS can be used to detect 38 MPXV in wastewater. We conducted WBS for MPXV in 22 wastewater treatment plants 39 (WWTPs) over a period of 14 weeks. Nucleic acids were extracted using the 40 MagAttract PowerMicrobiome DNA/RNA extraction kit. Three real-time gPCR assays 41 were assessed for the detection of MPXV in wastewater. These included the G2R 42 assays (G2R_WA and G2R_G) developed by the Centers for Disease Control and 43 Prevention (CDC) in 2010, as well as an in-house-developed assay (G2R NML). The 44 45 G2R G (generic) assay was designed to detect both the Congo and West African clades (re-named to Clades one and two, respectively) of viruses while the G2R WA 46 assay was designed to detect the West African clade (Clade one). The G2R NML 47 assay was designed using reference genomes of the 2022 MPXV outbreak. Our results 48 show that all three assays have similar limits of detection and are all able to detect the 49 presence of MPXV in wastewater. Following detection through real time gPCR, Sanger 50 51 sequencing was performed on the resulting amplicon products, with the assembled 52 contigs then undergoing analysis using nucleotide Basic Local Alignment Search Tool (BLAST). Due in part to the longer amplicon size of the G2R_NML assay, a significantly 53 greater number of positive detections were identified as originating from MPXV 54 55 compared to the CDC G2R assays. The ability to detect trace amounts of MPXV in wastewater as well as obtain Sanger sequence confirmation, has allowed for the 56 successful surveillance of this virus in wastewater. 57

58

It is made available under a CC-BY-NC 4.0 International license .

60 Introduction

61

The WHO has declared the current Monkeypox (MPXV) outbreak as a Public 62 Health Emergency of International Concern¹. As of the writing of this report, 61,827 63 cases have been reported in 97 countries that are largely non-endemic for this disease². 64 MPXV was first identified in nonhuman primates in 1958 in a research setting ³, and the 65 first human clinical case was identified in 1970 in the former province of Équateur, 66 67 which is now known as the Democratic Republic of the Congo⁴. The first clinical case was later confirmed by serological investigation as MPXV⁵. Cases have since been 68 69 generally well controlled and limited to the central west African region. Additional cases have been reported outside of this region in the UK, Israel and Singapore, with a 70 notable 2003 outbreak linked to pet prairie dogs in the US⁶. 71 72 MPXV is a member of the Poxviridae family of DNA viruses, the Orthopoxviridae genus to which it belongs includes smallpox and whose waning global acquired immunity has 73 been implicated in its spread^{7,8}. Small mammals and primates are implicated as the 74 hosts for MPXV and the natural reservoir is undefined⁹. MPXV has been detected in 75 pox lesions, the upper respiratory tract, blood, urine, feces, and semen in infected 76

⁷⁷ individuals linked to the 2022 outbreak^{10,11}.

The virus contains a 197 kb double stranded DNA genome packaged into a 200 x 250 nm virion that is described as "brick-like"^{7,12}. MPXV is currently divided into three clades^{12,13}; clade 1 (formerly Congo Basin clade) is typified by increased transmissibility and a higher case fatality ratio¹⁴. Clade 2 (formerly West African clade) tends to cause a milder disease and exhibits reduced transmissibility¹⁵. Isolates from the recent 2017 to 2019 outbreaks form the foundation for clade 3 and include cases from the on-going 2022 multi-country outbreak.

Molecular detection of MPXV by PCR has been elaborated in several studies describing
assays that are genus, species, or clade specific^{16–20}. The National Microbiology
Laboratory, Canada's national public health high-containment facility, supported clinical
diagnosis of MPXV via four diagnostic assays; the B6R¹⁶ assay and G2R_G¹⁸ assays
are species-specific assays directed at the envelope protein and TNF receptor,

It is made available under a CC-BY-NC 4.0 International license .

respectively. The G2R_WA¹⁸ assay is also directed at the TNF receptor gene and is
specific to the clade 2 and 3, while the C3L¹⁸ assay is directed at the complement
binding protein and is specific to the clade 1.

Limited testing, a wide range of disease presentation and stigmatized transmission 93 amongst men who have sex with men (MSM)^{10,11,21,22} has likely increased the global 94 95 spread of MPXV and alternate strategies are required to monitor the global spread of MPXV to prioritize infection control practices. Since the first detection of SARS-CoV-2 96 97 in sewage²³, wastewater-based epidemiology has been an effective means to provide early-warning and trending of COVID-19 in congregant living settings, small and large 98 99 communities that have been communicated in hundreds of articles too numerous to provide here. The multiple shedding routes of MPXV, including stool shedding, present 100 101 an opportunity to apply WBS to current MPXV outbreak. In this work, we compare the performance of the previously described G2R WA and G2R G assay described by Li 102 103 and co-workers¹⁸ with a novel assay named G2R_NML. We then apply this assay to demonstrate through limited surveillance across various Canadian cities that signal 104 105 derived from both these assays provide public health value by providing forewarning on the appearance of clinical cases. 106

107

108 Materials and Methods

109

110 Sewage sample collection

111

Influent 24 hr-composite wastewater samples were collected from 10 anonymized 112 Canadian cities with collection dates ranging from June 28 to September 30th, 2022. 113 Some 22 wastewater treatment plants were included in the study, where a major 114 115 metropolitan center in 9 of 10 Canada's provinces, one province was represented by two cities. Population coverages for each province ranged between 21% to 57% 116 117 (median coverage of 22 %), some 23% of all Canadians were represented in this study. Typically for most sites, two sewage samples were processed weekly from all locations. 118 119 Flow data was also collected from these six communities. Samples were collected in sterile 500 mL polyethylene terephthalate (PET) bottles and were shipped to the 120

It is made available under a CC-BY-NC 4.0 International license .

National Microbiology Laboratory at 4°C. Samples were stored at 4°C in the dark until
 and processed within two days of receipt (Figure 1).

123

124 Sample processing and nucleic acid isolation

125

We had initially attempted to survey for the MPXV signatures in wastewater in two epi-126 centers of the infections over the period of May through June 2022 and were unable to 127 garner any signal (Data not shown). Briefly, the assay conditions were to extract either 128 the insoluble material evolved from centrifugation of 30 mL of raw wastewater, or, 129 through concentration of 15 mL of wastewater using a 10 kDa centrifugal filter device. 130 In both cases nucleic acid was extracted using the Roche MP96 extraction platform 131 using the DNA and Viral NA Large Volume extraction kit and detection using the 132 G2R_WA assay described by Li and co-workers. Only when we increased the 133 134 processed volume to 200 mL and used the Qiagen PowerMicrobiome extraction kit 135 were we able to detect MPXV in Canadian wastewater. This change was inspired by a social media post from Dr. Alexandria Boehm's group reporting on positive detections of 136 MPXV in California and most recently reported as a pre-print using a method targeting 137 the settled solids of wastewater. The group has since published a pre-print article²⁴ that 138 states that MPXV is present 10³ times more in the insoluble vs soluble fraction of 139 wastewater, which is supported by the work presented here. 140

A 200 mL sample of well-mixed primary influent was centrifuged for 30 min at 12,000 x 141 g at 4°C to yield a pellet mass that was used for subsequent processing. Nucleic acids 142 were isolated from the wastewater solids using the MagAttract PowerMicrobiome 143 144 DNA/RNA extraction kit (Qiagen, Hilden, Germany) on the Kingfisher Flex (ThermoFisher Scientific, Waltham, MA). The pellets were re-suspended in 650 µL of 145 heated MBL solution containing 2.5% 2-mercaptoethanol and transferred to a 2 mL 146 PowerBead Pro tube (Qiagen, Hilden, Germany). Individual bead beating tubes were 147 chosen over the plate format to improve lysis and recovery²⁵. The pellet-bead mixture 148 was processed using a Bead Mill 24 Homogenizer (Fisher Scientific, Ottawa, ON) at 6 149 m/s for three 60 s cycles with a 10 s rest. Manufacturers' recommendations were 150

It is made available under a CC-BY-NC 4.0 International license .

- followed after sample lysis with the addition of 2 uL of \geq 9 mg/mL carrier RNA to each
- 152 well (Sigma-Aldrich, Oakville, ON). The median effective sample volume was 128.6 mL
- due to lysate produced in excess of the maximum loading volume (450 uL).
- 154

155 Real-time qPCR assay development and validation

156

Primers and probes (Table 1) for the G2R NML real-time gPCR assay were developed 157 *in silico* using PrimerQuest[™] Tool from Integrated DNA Technologies (IDT). The target 158 gene for this assay is the MPXV G2R gene (1050 bp in length) on the MPXVgp190 159 locus of the Clade 2 viral genome. Using GenBank, we obtained the first complete 160 MPXV genome sequence (MPXV_USA_2022_MA001; accession ON563414) of the 161 current 2022 MPXV outbreak and used it as a reference genome to develop the 162 G2R_NML assay. To determine assay specificity, the primers and probes were run 163 through NCBI BLAST. Additionally, utilizing the GISAID genome database, we obtained 164 165 supplementary MPXV genomes from the current outbreak and used them as reference genomes to determine the specificity (*in silico*) of the G2R_NML assay. Additionally, 166 we tested the MPXV gPCR assays developed by Li et al¹⁸ and compared their 167 168 performance to the G2R_NML assay.

169

170 Real-time qPCR

171

Primer and probe sequences are shown in Table 1. Assay conditions for the three 172 MPXV qPCR assays were as follows: qPCR was performed in a reaction volume of 20 173 µL, consisting of 5 µL QuantiNova Multiplex PCR Kit (Qiagen, Hilden, Germany), 400 174 nM (G2R G, G2R WA) and 300 nM (G2R NML) final concentration of each respective 175 primer set (ThermoFisher Scientific); 200 nM (G2R_G, G2R_WA) and 250 nM 176 (G2R NML)) of each probe (ThermoFisher Scientific); and 5 µL of template DNA and 177 178 Invitrogen nuclease-free H₂O (ThermoFisher Scientific). PCR amplification and detection of amplification products was performed on a QuantStudio 5 Real-time PCR 179 instrument (ThermoFisher Scientific). Thermal cycling conditions were as follows: 180

It is made available under a CC-BY-NC 4.0 International license .

polymerase activation at 95°C for 2 min, followed by 40 cycles of 95°C for 5 s and 60°C
for 30 s. Each real-time PCR was performed in triplicate with the appropriate nontemplate controls and positive controls. Results were considered positive if they had a
Ct value <40 (25). A standard curve was prepared for each target by preparing a five-
point serial dilution (50,000 – 5 cp/rxn) of linearized plasmid containing the plasmid
sequence (Thermofisher) (Table 2) with nuclease-free water and qPCR was run in
triplicate for each point.

188

189 Assay Sensitivity

Standard reference material in the form of synthetic DNA fragments were created 190 191 (Thermofisher Scientific) to support assay development and evaluation and were designed against G2R G, G2R WA, and G2R NML target regions (Table 2). The 192 three MPXV standards consisted of 200 bp regions unique to the primer probe sets. 193 which were inserted into individual pMA-RQ (AmpR) GeneArt cloning vectors 194 (Thermofisher Scientific). These plasmids were linearized using a high-fidelity Scal 195 restriction enzyme (New England BioLabs) and were purified using the QIAquick PCR 196 Purification Kit (Qiagen). TapeStation DNA ScreenTape (Agilent) was run on the 197 plasmid constructs to confirm linearity. Standards were quantified using the Absolute 198 199 Q[™] Digital PCR System (ThermoFisher) following manufacturers' recommendations. Assay limits of detection (ALOD)²⁶ were determined by measuring the relationship 200 201 between positivity rates of standardized qPCR reactions across a 13 point serial dilution 202 of standard reference material (as described above, see Table 2) from 45 copies/reaction (cp/rxn) to 0.1 cp/rxn. For each reference material concentration, 20 203 204 replicates were performed and a Ct value of < 40 was deemed to be a positive detection. A Probit model was fit to positivity rates for each assay and the ALOD was 205 determined from where the regression model intersected with a 95% positivity rate. The 206 ALOD confidence interval was estimated from where the regression model's confidence 207 interval intersected at the 95% assay positivity. The Assay Limit of Quantification 208 (ALOQ)²⁶ was determined by measuring the relationship between the coefficient of 209 variance of standardized qPCR reactions across an 11 point serial dilution of standard 210

It is made available under a CC-BY-NC 4.0 International license .

reference material from 45 to 3.95 cp/rxn. Reaction positivity and standard reference
 material are as described above. Coefficient of variation (CV) was calculated according
 to equation below.

214
$$CV = \sqrt{1 + E^{\sigma_{Cq}^2 * \ln(1+E)} - 1}$$

Where E is the PCR efficiency as described above, $\sigma_{c_q}^2$ is the Cq standard deviation of the cycle thresholds corresponding to a specific concentration. The CV for each assay was fit to a linear regression model against the log₁₀ cp/rxn and the determined CV for each reaction. The ALOQ was where the line of best fit intersected with a CV of 35%.

The sample limit of detection²⁶ (SLOD) and sample limit of quantification²⁶ (SLOQ) was calculated using the median effective sample volume, template volume, and extraction volume (100 uL) – see $also^{27}$.

222

223 Sanger sequencing of real-time qPCR products

224

Triplicate gPCR amplification products were pooled into a total volume of 60 µL. Pooled 225 226 amplicons were purified using Ampure XP Reagent (Beckman Coulter catalog number: A63881) following the manufacturers' instructions, with a modified elution volume of 20 227 μL. A volume of 1 μL of purified amplicon was Sanger-sequenced using BigDye-228 TerminatorTM v3.1 Cycle Sequencing Reaction Kit on a 3730 xl Genetic Analyzer 229 230 (Applied Biosystems, Foster City, CA, USA) following the manufacturer's instructions. 231 PCR sequences were aligned using the Seqman Pro15 assembly program as part of the DNASTAR Lasergene 15 software suite. Assembled contigs were analyzed with 232 nucleotide Basic Alignment Search Tool (BLAST) assigned to megablast optimization 233 for highly similar sequences. Query results were analyzed for top matches related to 234 Monkeypox specific query results with equal to or greater than 95% bp query coverage 235 and equal to or greater than 95% identification. 236

237 Clinical case data

It is made available under a CC-BY-NC 4.0 International license .

- 239 First case reported dates were gathered from an online web-portal
- 240 https://www.canada.ca/en/public-health/services/diseases/monkeypox.html.

241 **Results**

242

To augment the complement of qPCR assays to address the emerging MPXV 243 244 outbreak, a gPCR assay was designed against the TNF receptor gene located within the 5' and 3' terminal repeats of the virus, named G2R NML. The previously published 245 G2R WA assay targets this same loci¹⁸ and indeed the reverse primer of the 246 G2R_NML and the forward primer of the G2R_WA overlap. Figure 2a and 2b depict 247 alignments of all of these assays' primer and probe sequences against a panel of Clade 248 2 genomes drawn from recently sequenced genomes of the 2022 outbreak. Seven 249 250 nucleotides of the 5' probe of the previously published G2R WA assay are noncomplementary when aligned to a panel of Clade 1 genomes, as this design feature 251 affords the discriminatory ability of this assay against Clade 1 and Clade 2 variants 252 (Figure 2C). Figure 2d shows the alignment of the G2R_G assay against Clade 1 253 254 genomes, which shows its ability to also detect this MPXV clade. The amplicon sizes of 255 the G2R_NML and G2R_WA assays are 136bp and 85bp, respectively (Table 1). The G2R_G assay from Li et al (18), which can detect both clade 1 and 2 variants, was also 256 257 employed in this work.

The log-linear slope, intercept, linear correlation, and PCR efficiencies of all of the above assays is described in Table 3. The slopes for each assay ranged from –3.43 to -3.55, and delivered PCR efficiencies of 91% to 96%. The correlation coefficient across all assays ranged from 0.9956 to 0.9976. Intercepts across all assays ranged between 37.30 and 38.13, and none of the no-template control runs for each assay registered as positive.

The ALOD (95% CI) for the G2R_G, G2R_WA and G2R_NML assays were 3.52 (2.47, 6.03), 3.47 (2.37, 6.28) and 3.48 (2.42, 6.03) cp/rxn, respectively (see Figure 3A-C, vertical black line). This very closely matches what Li et *al*¹⁸ found in their study where they report LOD values of ~3.5 and ~8.2 genomes from the G2R_G and G2R_WA assays, respectively. This implies a SLOD (95% CI) for the G2R_G, G2R_WA and

It is made available under a CC-BY-NC 4.0 International license .

269 G2R_NML assays were 0.55 (0.39, 0.94), 0.54 (0.37, 0.98) and 0.54 (0.38, 0.94) cp/mL.

The ALOQ for the G2R G, G2R WA and G2R NML assays were 17.2, 19.9 and 20.1

cp/rxn, respectively (see Figure 3D-F, vertical black line). The SLOQ for the G2R_G,

272 G2R_WA and G2R_NML assays were 2.68, 3.11 and 3.14 cp/mL.

- For each assay, triplicates from qPCR positive wastewater samples were pooled and
- Sanger sequenced, then aligned to Monkeypox via BLAST analysis. The sequence
- confirmation rates for the G2R_G, G2R_WA, and G2R_NML assays were 16%, 22%,
- and 76%, respectively (X^2 p-value = 89.9 (3.07×10⁻²⁰), Table 4). Negative result
- 277 denotes a false positive or a sequence fail.

278 The viral load from wastewater samples drawn from all communities tested in this work were determined using the G2R_G, G2R_WA and G2R_NML assays in triplicate. The 279 distribution of the censored geometric mean of replicate viral loads for all samples 280 collected from July 7th to August 25th is presented in Figure 4A-left. The sample mean 281 for the G2R G, G2R WA and G2R NML assays were 0.52, 0.45, and 0.51 cp/mL. 282 respectively. These values were supported by Ct values of 36.3, 36.1 and 35.6 for the 283 G2R_G, G2R_WA and G2R_NML assays, respectively (Figure 4A-right). Spearman's 284 correlations and a pair-wise comparison for all assays is presented in Figure 4 B-D. 285 The correlations were as follows G2R_WA:G2R_NML was 0.717, G2R_G:G2R_WA 286 was 0.754, and G2R G:G2R NML was 0.755. 287

All positive samples were submitted for Sanger sequencing. As described in Table 4, the % positivity rate for G2R_G, G2R_WA and G2R_NML, was 16%, 28% and 76%.

Comparison of assay positivity across all three assays across all sites tested during the 290 291 study period are represented in Figure 5. A major metropolitan center in nearly each Canadian province was tested over the 14 week study period. For one province, two 292 city sites were tested (Figure 5 – "Province D"). If any wastewater treatment plant 293 registered as positive for the week in a province, the entire week was marked as 294 positive (Figure 5 – red boxes). For 5 provinces the first clinical detection was outside 295 296 the study period for this work. For provinces D and H wastewater detection of MPXV was 7 and 3 weeks prior to clinical detection, respectively. For province G and I 297

It is made available under a CC-BY-NC 4.0 International license .

wastewater detection of MPXV was 5 and 1 weeks following the first clinical detection,respectively.

300

301 Discussion

302

303 Currently, information on the fecal shedding of MPXV is limited. Adler et al have shown that MPXV DNA can be found in the upper respiratory tract, blood and urine of 304 infected patients¹⁰, while Antinori *et al* have shown that MPXV DNA can be found in 305 seminal fluid and feces as well¹¹. Its widespread bodily secretion and excretion suggest 306 307 the possibility that this virus can be tracked using WBS. With limited capacity for clinical testing and the stigma often associated with this illness, WBS can act as a 308 309 complimentary surveillance tool not only to enhance surveillance efforts but also to provide a fulsome picture of the extent of MPX activity. 310

In this work, we demonstrate that the G2R_NML assay is complementary to both 311 G2R G and G2R WA from Li and co-workers¹⁸ for detection of MPXV in wastewater. 312 All assays have similar LODs and LOQs, and correlate well with each other as 313 demonstrated by the high Spearman correlation. Most of the detections in this work 314 were below the SLOD and SLOQ, despite a clear correlation across all assays. For this 315 reason we favored interpretation of the data as a binary signal driven by assay 316 317 positivity. MPXV wastewater signals were a leading indicator of reported clinical cases 318 at the provincial level at provincial sites D and H and closely correlated with clinical detection at provincial site I. At provincial site G wastewater lagged considerably from 319 320 clinical detection, although the lack of geo-location of clinical signal hampers precise interpretation. These data could be supportive of informing the allocation of resources 321 322 such as vaccines to vulnerable populations with the areas of detection.

The specific advantage of NML-developed assay is that amplicons are more easily confirmed by Sanger sequencing. Likely, because the design of this assay has a slightly larger amplicon (136 vs 85/90 bp). This increase does not impact the qPCR efficiency, and the ALOD and ALOQ are comparable to the CDC assays. Amplicons

It is made available under a CC-BY-NC 4.0 International license .

derived from environmental surveillance are a challenge to sequence due to the high-327 diversity of DNA in samples, which can lead to off-target amplification that inhibit 328 sequencing efforts. This is made doubly difficult as signals tend to be at the technical 329 limitations of qPCR. Sub-cloning amplicons is a viable but cumbersome route to 330 garnering sequence confirmation. Since the current Monkeypox outbreak is an 331 332 emerging and high-consequence issue for public health decision makers, timely access to sequence confirmation of emerging signals promotes uptake of this novel data 333 stream. A recent study conducted by de Jonge *et al*²⁸ describes an elegant approach to 334 confirm the qPCR signals obtained from MPXV detection in wastewater. In brief, a 335 semi-nested gPCR was used to generate amplicons using the forward primer of the 336 G2R G and the reverse primer of the G2R WA assays. The product was then put 337 338 through another round of amplification using the G2R_G probe and G2R_WA reverse primer to generate an amplicon that could be Sanger sequenced²⁸. Additionally, the 339 340 distribution of Cts for the G2R NML assay is lower than the G2R G and G2R WA assays, suggesting that the performance of this assay is at least sensitive and perhaps 341 342 more sensitive than the above mentioned assays. In sum, we feel that the G2R NML assay can act as a complement to developing MPXV wastewater surveillance systems. 343

344

Finally, for COVID-19 WBS, many groups include two targets as part of their assay
regiment to mitigate the inherent variable nature of WBS and the risk of mutation.
Given that there are indications that the recent Monkeypox outbreak could be driven inpart by a higher mutational frequency¹², a second assay as part of a WBS surveillance
program is a means to mitigating loss of sensitivity due to mutation. The CDC assays
afford high sensitivity, yet the route to confirmation has proven challenging. The
G2R_NML assay could be a useful tool when this confirmation is required.

The Boehm group and others^{29,30} have been advocates for WBS assay designs that extract genetic material from either the settled solids from primary influent/raw sewage or through high-solids samples sampled from the primary clarifier. The high prevalence and attack rate of SARS-CoV-2 have likely allowed for smaller process volumes to support COVID-19 surveillance that is minimally tracking clinical cases and

It is made available under a CC-BY-NC 4.0 International license .

hospitalizations. However, the current MPXV outbreak shows that higher process 357 358 volumes that are directed to the insoluble fractions are an operational necessity. To reorient WBS systems to the process of high-solids contents is difficult as larger sample 359 volumes are required to garner adequate material for processing, which can complicate 360 sample collection, increase overhead of laboratory management and reduce throughput 361 over smaller sample volumes. Standard methods to concentrate solid material at the 362 363 point of sampling are a potential solution to alleviate the logistical burden of shipping 364 large volumes of wastewater to support a central-laboratory model of WS.

To further develop MPXV WBS, several open questions should be answered; the 365 366 stability of the virus across temperature and time should be performed, as it was for SARS-CoV-2. This will help define hold-times that ultimately limit/define the 367 surveillance structure. Furthermore, an epidemiological useful scheme to track the 368 369 mutations profile through metagenomics-like methods is required. As MPXV is a large 370 virus this will likely be an onerous task. However, focusing on the immunologically relevant regions may be a route to an efficient and informative design, this is supported 371 372 by observations that a signature change in MPXV genome over this recent outbreak have been changes to surface antigens present in the virus. 373

Future work to test the stability of the virus in wastewater is still required. Additionally, 374 while we made every attempt to make the G2R NML assay specific to MPXV by in 375 376 silico analysis, cross-reactivity studies involving other orthopoxvirus targets are still 377 required. Also, further comparisons between clinical and wastewater signal trends are needed. Correspondence to clinical surveillance would be useful in further establishing 378 the confidence of this assay, however, stigmatization could erode this correspondence. 379 380 Case reported dates may be temporally separated from peak fecal shedding which is 381 likely at the onset of symptomology. This necessitates careful follow-up studies as correspondence between clinical and wastewater signals requires both a temporal and 382 383 spatial element.

The WBS for MPXV will enable jurisdictions to monitor the virus in their sewershed even when no clinical cases are known to be present. This will help make important resource allocation decisions in the current context when the system is overwhelmed with the

COVID-19 response. With no MPXV signal in wastewater, other public health prioritiescan be supported with more confidence.

389 **Conclusions**

390 The cause of the 2022 MPXV worldwide outbreak is not well understood. However, it

- highlights the fact that additional surveillance tools are necessary to better track and
- help contain its spread. This work suggests that WBS can be used as a viable
- 393 surveillance strategy for the current MPXV outbreak.

394 Acknowledgements

- We acknowledge the work of Jason Agasid for the quantification of the standard
- 396 material. We acknowledge our collaboration with Statistics Canada for joint collection of
- 397 wastewater through Canadian Wastewater Survey. We thank the municipalities for
- ³⁹⁸ providing wastewater and participating Public Health authorities.

399

400

401

It is made available under a CC-BY-NC 4.0 International license .

403 Figures and Tables

404

- **Table 1**: G2R_G, G2R_WA, G2R_NML primers and probes sequences, final
- 406 concentrations and amplicon lengths.

Target	Primer/probe	Sequence	Final Concentration (nM)	Amplicon size (bp)	Reference
	F	GGAAAATGTAAAGACAACGAATACAG	400		
G2R_G	R	GCTATCACATAATCTGGAAGCGTA	400	90	Li et al. 2010
	Р	FAM-AAGCCGTAATCTATGTTGTCTATCGT-MGB	200		2010
	F	GGAAAATGTAAAGACAACGAATACAG	400		
G2R_WA	R	GCTATCACATAATCTGGAAGCGTA	400	85	Li et al. 2010
_	Р	FAM-AAGCCGTAATCTATGTTGTCTATCGT-MGB	200		2010
	F	AGGAGCATCAGGGTGTAGAA	400		
G2R_NML	R	GGAAGAGACGGTGTGAGAATATG	400	136	In-house
	Р	FAM-CGTCATCTGTTCTCCGTGTGGTCC-MGB	200		

- 407
- 408

409

410 **Table 2**: MPXV 200bp DNA fragments for G2R_G, G2R_WA, and G2R_NML targets.

Target(s)	Quantitation Standard Sequence
G2R_G	CTCGTATATATTGTTTCTCTCATGTATAATAATAAACGGAAGAGATATAGCACCACATGCACCATCCAA TGGAAAGTGTAAAGACAACGAATACAGAAGCCGTAATCTATGTTGTCTATCGTGTCCTCCGGGAACTT ACGCTTCCAGATTATGTGATAGCAAGACTAATACACAATGTACACCGTGTGGTTCGGATACCT
G2R_WA	CGGATACACGTCTACCGGAGACGTCATCTGTTCTCCGTGTGGTCCCGGAACATATTCTCACACCGTCTC TTCCACAGATAAATGCGAACCCGTCGTAACCAGCAATACATTTAACTATATCGATGTGGAAATTAACCT GTATCCAGTCAACGACACATCGTGTACTCGGACGACCACTACCGGTCTCAGCGAATCCATCT
G2R_NML	GAATCTGTGAATGCTCTCCAGGATATTATTGTCTTCTCAAAGGAGCATCAGGGTGTAGAACATGTATT TCTAAAACAAAGTGTGGAATAGGATACGGAGTATCCGGATACACGTCTACCGGAGACGTCATCTGTTC TCCGTGTGGTCCCGGAACATATTCTCACACCGTCTCTTCCACAGATAAATGCGAACCCGTCGTA

It is made available under a CC-BY-NC 4.0 International license .

Table 3: Real time qPCR assay parameters for G2R_G, G2R_WA, and G2R_NML


Target	Slope	Intercept	RSQ	Efficiency
G2R_G	-3.55	38.13	0.9956	91%
G2R_WA	-3.49	37.62	0.9959	93%
G2R_NML	-3.43	37.30	0.9976	96%

Table 4: Proportion of positive real time qPCR signals that were confirmatory for MPXV

416 via Sanger sequence analysis.

Monkeypox Sequence Match	G2R_G (%)	G2R_WA (%)	G2R_NML (%)	X ² (p-value)
Negative	82 (84)	98 (78)	27 (26)	<u>90 0 (2 07: 10⁻²⁰)</u>
Positive	16 (16)	28 (22)	76 (74)	89.9 (3.07×10 ⁻²⁰)

It is made available under a CC-BY-NC 4.0 International license .




424

- 425 **Figure 1 Workflow to detect MPXV in wastewater.** Step 1 includes centrifuging 200 mL of sewage to
- 426 obtain a solids pellet that is bead-beaten in a tube containing lysis buffer and silica-zirconium beads.
- 427 Step 2 depicts DNA isolation on the KingFisher Flex using the Qiagen MagAttract PowerMicrobiome kit.
- 428 Step 3 utilizes qPCR to detect and quantify MPXV targets. Following qPCR, the amplicons are Sanger
- 429 sequence confirmed.
- 430
- 431
- 432

433

434

It is made available under a CC-BY-NC 4.0 International license .




It is made available under a CC-BY-NC 4.0 International license .

- 439 primers and probes to the TNF receptor genes from reference Clade one MPXV genomes. Identity graph
- 440 illustrates pairwise-identity homology (green = match, light brown = mis-match). Purple graph illustrates
- the inverted terminal repeat (ITR) region. Image created using Geneious Prime[®] version 2022.0.2.

442

It is made available under a CC-BY-NC 4.0 International license .





445 (A-C) Positivity rates of the 3 assays obtained from a 15 serial dilution were fitted to a Probit regression

446 for the estimation of the LoD (solid blue line). The 95% confidence interval from the regression fit (grey

447 band) allows estimating the 95% confidence interval for the LoD (orange and purple dashed line). (D-F)

448 Coefficient of variance of the 3 assays obtained from a 15 serial dilution were fitted to a linear

449 regression for the estimation of the LoQ (solid blue line).

It is made available under a CC-BY-NC 4.0 International license .







Figure 4 – Performance of MPXV qPCR assays. (A-left) Viral load distributions and supporting (A-right)
Cts across the indicated assays for all communities tested is presented as a box and whisker box plot;
the edges of the box of indicate the upper and lower quartiles, the whiskers extend to the values that
are no further than 1.5 times the interquartile range, observations outside the whisker extent are
represented by a dot. (B-D) Pair-wise comparison of log-transformed unadjusted viral loads for assays
as indicated on the axes, non-detects are presented on their respective axis line. Spearman correlation
for each pair-wise comparison are indicated above each plot.

It is made available under a CC-BY-NC 4.0 International license .



459

460 Figure 5 – Comparison of MPXV detections in wastewater across Canada and first clinical detections.

461 Each row of the diagram represents surveillance in a major metropolitan centre for 9 Canadian

462 provinces, except for province D where two cities represent the province. Each box in the matrix

diagram represents a week of surveillance; for each week wastewater samples were tested across the

three PCR assays described in this work, a positive detection by any assay is represented in red, a

negative detections across all assays are represented in blue, and grey boxes indicate no sample was

466 received from the site. The first clinical detection reported at the provincial for each site during the

467 study period are indicated by a green box, where first clinical detection was outside the bounds of this

468 work are indicated by a green circle to the left of the diagram.

It is made available under a CC-BY-NC 4.0 International license .

471 **References**

473 474 475 476 477 478	(1)	WHO Director-General's statement at the press conference following IHR Emergency Committee regarding the multi-country outbreak of monkeypox - 23 July 2022. https://www.who.int/news-room/speeches/item/who-director-general-s- statement-on-the-press-conference-following-IHR-emergency-committee- regarding-the-multicountry-outbreak-of-monkeypox23-july-2022 (accessed 2022-07-30).
479 480 481	(2)	2022 Monkeypox Outbreak Global Map Monkeypox Poxvirus CDC. https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html (accessed 2022-07-30).
482 483 484	(3)	Magnus, P. von; Andersen, E. K.; Petersen, K. B.; Birch-Andersen, A. A POX- LIKE DISEASE IN CYNOMOLGUS MONKEYS. <i>Acta Pathol. Microbiol. Scand.</i> 1959 , <i>46</i> (2), 156–176. https://doi.org/10.1111/J.1699-0463.1959.TB00328.X.
485 486 487	(4)	Ladnyj, I. D.; Ziegler, P.; Kima, E. A Human Infection Caused by Monkeypox Virus in Basankusu Territory, Democratic Republic of the Congo. <i>Bull. World Health Organ.</i> 1972 , <i>46</i> (5), 593.
488 489 490	(5)	Marennikova, S. S.; Seluhina, E. M.; Mal'ceva, N. N.; Cimiskjan, K. L.; Macevic, G. R. Isolation and Properties of the Causal Agent of a New Variola-like Disease (Monkeypox) in Man. <i>Bull. World Health Organ.</i> 1972 , <i>46</i> (5), 599.
491 492 493 494	(6)	Bunge, E. M.; Hoet, B.; Chen, L.; Lienert, F.; Weidenthaler, H.; Baer, L. R.; Steffen, R. The Changing Epidemiology of Human Monkeypox—A Potential Threat? A Systematic Review. <i>PLoS Negl. Trop. Dis.</i> 2022 , <i>16</i> (2), e0010141. https://doi.org/10.1371/JOURNAL.PNTD.0010141.
495 496	(7)	Prier, J. E.; Sauer, R. M. A POX DISEASE OF MONKEYS. <i>Ann. N. Y. Acad. Sci.</i> 1960 , <i>85</i> (3), 951–959. https://doi.org/10.1111/J.1749-6632.1960.TB50015.X.
497 498 499	(8)	Shchelkunov, S. N. An Increasing Danger of Zoonotic Orthopoxvirus Infections. <i>PLOS Pathog.</i> 2013 , <i>9</i> (12), e1003756. https://doi.org/10.1371/JOURNAL.PPAT.1003756.

It is made available under a CC-BY-NC 4.0 International license .

500 501	(9)	Gong, Q.; Wang, C.; Chuai, X.; Chiu, S. Monkeypox Virus: A Re-Emergent Threat to Humans. <i>Virol. Sin.</i> 2022 . https://doi.org/10.1016/J.VIRS.2022.07.006.
501		to Humans. <i>Virol. 3in.</i> 2022 . https://doi.org/10.1010/J.VIR3.2022.07.000.
502	(10)	Adler, H.; Gould, S.; Hine, P.; Snell, L. B.; Wong, W.; Houlihan, C. F.; Osborne, J.
503		C.; Rampling, T.; Beadsworth, M. B.; Duncan, C. J.; Dunning, J.; Fletcher, T. E.;
504		Hunter, E. R.; Jacobs, M.; Khoo, S. H.; Newsholme, W.; Porter, D.; Porter, R. J.;
505		Ratcliffe, L.; Schmid, M. L.; Semple, M. G.; Tunbridge, A. J.; Wingfield, T.; Price,
506		N. M.; Abouyannis, M.; Al-Balushi, A.; Aston, S.; Ball, R.; Beeching, N. J.;
507		Blanchard, T. J.; Carlin, F.; Davies, G.; Gillespie, A.; Hicks, S. R.; Hoyle, MC.;
508		llozue, C.; Mair, L.; Marshall, S.; Neary, A.; Nsutebu, E.; Parker, S.; Ryan, H.;
509		Turtle, L.; Smith, C.; van Aartsen, J.; Walker, N. F.; Woolley, S.; Chawla, A.; Hart,
510		I.; Smielewska, A.; Joekes, E.; Benson, C.; Brindley, C.; Das, U.; Eyton-Chong, C.
511		K.; Gnanalingham, C.; Halfhide, C.; Larru, B.; Mayell, S.; McBride, J.; Oliver, C.;
512		Paul, P.; Riordan, A.; Sridhar, L.; Storey, M.; Abdul, A.; Abrahamsen, J.; Athan,
513		B.; Bhagani, S.; Brown, C. S.; Carpenter, O.; Cropley, I.; Frost, K.; Hopkins, S.;
514		Joyce, J.; Lamb, L.; Lyons, A.; Mahungu, T.; Mepham, S.; Mukwaira, E.; Rodger,
515		A.; Taylor, C.; Warren, S.; Williams, A.; Levitt, D.; Allen, D.; Dixon, J.; Evans, A.;
516		McNicholas, P.; Payne, B.; Price, D. A.; Schwab, U.; Sykes, A.; Taha, Y.; Ward,
517		M.; Emonts, M.; Owens, S.; Botgros, A.; Douthwaite, S. T.; Goodman, A.; Luintel,
518		A.; MacMahon, E.; Nebbia, G.; O'Hara, G.; Parsons, J.; Sen, A.; Stevenson, D.;
519		Sullivan, T.; Taj, U.; van Nipsen tot Pannerden, C.; Winslow, H.; Zatyka, E.;
520		Alozie-Otuka, E.; Beviz, C.; Ceesay, Y.; Gargee, L.; Kabia, M.; Mitchell, H.;
521		Perkins, S.; Sasson, M.; Sehmbey, K.; Tabios, F.; Wigglesworth, N.; Aarons, E.
522		J.; Brooks, T.; Dryden, M.; Furneaux, J.; Gibney, B.; Small, J.; Truelove, E.;
523		Warrell, C. E.; Firth, R.; Hobson, G.; Johnson, C.; Dewynter, A.; Nixon, S.;
524		Spence, O.; Bugert, J. J.; Hruby, D. E. Clinical Features and Management of
525		Human Monkeypox: A Retrospective Observational Study in the UK. Lancet
526		Infect. Dis. 2022, 22 (8), 1153–1162. https://doi.org/10.1016/S1473-
527		3099(22)00228-6.
528	(11)	Peiró-Mestres, A.; Fuertes, I.; Camprubí-Ferrer, D.; Marcos, M. Á.; Vilella, A.;

529 Navarro, M.; Rodriguez-Elena, L.; Riera, J.; Català, A.; Martínez, M. J.; Blanco, J.

It is made available under a CC-BY-NC 4.0 International license .

530 531 532 533		L.; Group, on behalf of the H. C. de B. M. S. Frequent Detection of Monkeypox Virus DNA in Saliva, Semen, and Other Clinical Samples from 12 Patients, Barcelona, Spain, May to June 2022. <i>Eurosurveillance</i> 2022 , <i>27</i> (28), 1. https://doi.org/10.2807/1560-7917.ES.2022.27.28.2200503.
534 535 536 537 538 539	(12)	 Isidro, J.; Borges, V.; Pinto, M.; Sobral, D.; Santos, J. D.; Nunes, A.; Mixão, V.; Ferreira, R.; Santos, D.; Duarte, S.; Vieira, L.; Borrego, M. J.; Núncio, S.; de Carvalho, I. L.; Pelerito, A.; Cordeiro, R.; Gomes, J. P. Phylogenomic Characterization and Signs of Microevolution in the 2022 Multi-Country Outbreak of Monkeypox Virus. <i>Nat. Med.</i> 2022. https://doi.org/10.1038/S41591-022-01907-Y.
540 541 542 543 544	(13)	Luna, N.; Ramírez, A. L.; Muñoz, M.; Ballesteros, N.; Patiño, L. H.; Castañeda, S. A.; Bonilla-Aldana, D. K.; Paniz-Mondolfi, A.; Ramírez, J. D. Phylogenomic Analysis of the Monkeypox Virus (MPXV) 2022 Outbreak: Emergence of a Novel Viral Lineage? <i>Travel Med. Infect. Dis.</i> 2022 , <i>49</i> , 102402. https://doi.org/10.1016/J.TMAID.2022.102402.
545 546 547 548 549	(14)	 Xing, Y. H.; Ni, W.; Wu, Q.; Li, W. J.; Li, G. J.; Wang, W. Di; Tong, J. N.; Song, X. F.; Wing-Kin Wong, G.; Xing, Q. S. Prolonged Viral Shedding in Feces of Pediatric Patients with Coronavirus Disease 2019. <i>Journal of Microbiology,</i> <i>Immunology and Infection</i>. Elsevier Ltd 2020. https://doi.org/10.1016/j.jmii.2020.03.021.
550 551 552	(15)	Di Giulio, D. B.; Eckburg, P. B. Human Monkeypox: An Emerging Zoonosis. <i>Lancet Infect. Dis.</i> 2004 , <i>4</i> (1), 15–25. https://doi.org/10.1016/S1473- 3099(03)00856-9.
553 554 555	(16)	Li, Y.; Olson, V. A.; Laue, T.; Laker, M. T.; Damon, I. K. Detection of Monkeypox Virus with Real-Time PCR Assays. <i>J. Clin. Virol.</i> 2006 , <i>36</i> (3), 194–203. https://doi.org/10.1016/J.JCV.2006.03.012.
556 557 558	(17)	Maksyutov, R. A.; Gavrilova, E. V.; Shchelkunov, S. N. Species-Specific Differentiation of Variola, Monkeypox, and Varicella-Zoster Viruses by Multiplex Real-Time PCR Assay. <i>J. Virol. Methods</i> 2016 , <i>236</i> , 215–220.

It is made available under a CC-BY-NC 4.0 International license .

559 https://doi.org/10.1016/J.JVIROMET.2016.07.024.

- (18) Li, Y.; Zhao, H.; Wilkins, K.; Hughes, C.; Damon, I. K. Real-Time PCR Assays for
 the Specific Detection of Monkeypox Virus West African and Congo Basin Strain
- 562 DNA. J. Virol. Methods **2010**, 169 (1), 223–227.
- 563 https://doi.org/10.1016/J.JVIROMET.2010.07.012.
- (19) Schroeder, K.; Nitsche, A. Multicolour, Multiplex Real-Time PCR Assay for the
 Detection of Human-Pathogenic Poxviruses. *Mol. Cell. Probes* 2010, *24* (2), 110–
 113. https://doi.org/10.1016/J.MCP.2009.10.008.
- 567 (20) Kulesh, D. A.; Loveless, B. M.; Norwood, D.; Garrison, J.; Whitehouse, C. A.;
- 568 Hartmann, C.; Mucker, E.; Miller, D.; Wasieloski, L. P.; Huggins, J.; Huhn, G.;
- 569 Miser, L. L.; Imig, C.; Martinez, M.; Larsen, T.; Rossi, C. A.; Ludwig, G. V.
- 570 Monkeypox Virus Detection in Rodents Using Real-Time 3'-Minor Groove Binder
- TaqMan Assays on the Roche LightCycler. *Lab. Invest.* 2004, *84* (9), 1200–1208.
 https://doi.org/10.1038/LABINVEST.3700143.
- 573 (21) Selb, R.; Werber, D.; Falkenhorst, G.; Steffen, G.; Lachmann, R.; Ruscher, C.;
 574 McFarland, S.; Bartel, A.; Hemmers, L.; Koppe, U.; Stark, K.; Bremer, V.; Jansen,
- 575 K.; group, on behalf of the B. M. study. A Shift from Travel-Associated Cases to
- 576 Autochthonous Transmission with Berlin as Epicentre of the Monkeypox Outbreak
- 577 in Germany, May to June 2022. *Eurosurveillance* **2022**, 27 (27), 2200499.
- 578 https://doi.org/10.2807/1560-7917.ES.2022.27.27.2200499.
- 579 (22) Girometti, N.; Byrne, R.; Bracchi, M.; Heskin, J.; McOwan, A.; Tittle, V.; Gedela,
- 580 K.; Scott, C.; Patel, S.; Gohil, J.; Nugent, D.; Suchak, T.; Dickinson, M.; Feeney,
- 581 M.; Mora-Peris, B.; Stegmann, K.; Plaha, K.; Davies, G.; Moore, L. S. P.; Mughal,
- 582 N.; Asboe, D.; Boffito, M.; Jones, R.; Whitlock, G. Demographic and Clinical
- 583 Characteristics of Confirmed Human Monkeypox Virus Cases in Individuals
- 584 Attending a Sexual Health Centre in London, UK: An Observational Analysis.
- 585 *Lancet Infect. Dis.* **2022**. https://doi.org/10.1016/S1473-3099(22)00411-X.
- Medema, G.; Heijnen, L.; Elsinga, G.; Italiaander, R.; Brouwer, A. Presence of
 SARS-Coronavirus-2 RNA in Sewage and Correlation with Reported COVID-19

- 588 Prevalence in the Early Stage of the Epidemic in the Netherlands. *Environ. Sci.*
- 589 *Technol. Lett.* **2020**, 7 (7), 511–516.
- https://doi.org/10.1021/ACS.ESTLETT.0C00357/ASSET/IMAGES/LARGE/EZ0C0
 0357_0002.JPEG.
- 592 (24) Kim, S.; Kennedy, L. C.; Wolfe, M. K.; Criddle, C. S.; Duong, D. H.; Topol, A.;
- 593 White, B. J.; Kantor, R. S.; Nelson, K. L.; Steele, J. A.; Langlois, K.; Griffith, J. F.;
- Zimmer-Faust, A. G.; McLellan, S. L.; Schussman, M. K.; Ammerman, M.;
- 595 Wigginton, K. R.; Bakker, K. M.; Boehm, A. B. SARS-CoV-2 RNA Is Enriched by
- 596 Orders of Magnitude in Primary Settled Solids Relative to Liquid Wastewater at
- 597 Publicly Owned Treatment Works. *Environ. Sci.* **2022**, 8 (4), 757.
- 598 https://doi.org/10.1039/D1EW00826A.
- 599 (25) Tourlousse, D. M.; Narita, K.; Miura, T.; Sakamoto, M.; Ohashi, A.; Shiina, K.;
- Matsuda, M.; Miura, D.; Shimamura, M.; Ohyama, Y.; Yamazoe, A.; Uchino, Y.;
- Kameyama, K.; Arioka, S.; Kataoka, J.; Hisada, T.; Fujii, K.; Takahashi, S.;
- 602 Kuroiwa, M.; Rokushima, M.; Nishiyama, M.; Tanaka, Y.; Fuchikami, T.; Aoki, H.;
- Kira, S.; Koyanagi, R.; Naito, T.; Nishiwaki, M.; Kumagai, H.; Konda, M.;
- Kasahara, K.; Ohkuma, M.; Kawasaki, H.; Sekiguchi, Y.; Terauchi, J. Validation
- and Standardization of DNA Extraction and Library Construction Methods for
- 606 Metagenomics-Based Human Fecal Microbiome Measurements. *Microbiome*
- 607 **2021**, 9 (1), 1–19. https://doi.org/10.1186/S40168-021-01048-3/FIGURES/4.
- 608 (26) Ahmed, W.; Bivins, A.; Metcalfe, S.; Smith, W. J. M.; Verbyla, M. E.; Symonds, E.
- M.; Simpson, S. L. Evaluation of Process Limit of Detection and Quantification
- 610 Variation of SARS-CoV-2 RT-QPCR and RT-DPCR Assays for Wastewater
- 611 Surveillance. *Water Res.* **2022**. https://doi.org/10.1016/j.watres.2022.118132.
- 612 (27) Agency, O. C. W. *The Protocol for Evaluations of RT-QPCR Performance*613 *Characteristics*; Chik, A. H. S., Ed.; 2022.
- 614 (28) de Jonge, E. F.; Peterse, C. M.; Koelewijn, J. M.; van der Drift, A. M. R.; van der
- Beek, R. F. H. J.; Nagelkerke, E.; Lodder, W. J. The Detection of Monkeypox
- Virus DNA in Wastewater Samples in the Netherlands. *Sci. Total Environ.* **2022**,

It is made available under a CC-BY-NC 4.0 International license .

617 852, 158265. https://doi.org/10.1016/J.SCITOTENV.2022.158265.

- 618 (29) Peccia, J.; Zulli, A.; Brackney, D. E.; Grubaugh, N. D.; Kaplan, E. H.; Casanovas-
- Massana, A.; Ko, A. I.; Malik, A. A.; Wang, D.; Wang, M.; Warren, J. L.;
- Weinberger, D. M.; Arnold, W.; Omer, S. B. Measurement of SARS-CoV-2 RNA in
- 621 Wastewater Tracks Community Infection Dynamics. *Nat. Biotechnol.* **2020**, 38
- 622 (10), 1164. https://doi.org/10.1038/S41587-020-0684-Z.
- (30) D'Aoust, P. M.; Mercier, E.; Montpetit, D.; Jia, J. J.; Alexandrov, I.; Neault, N.;
- Baig, A. T.; Mayne, J.; Zhang, X.; Alain, T.; Langlois, M. A.; Servos, M. R.;
- MacKenzie, M.; Figeys, D.; MacKenzie, A. E.; Graber, T. E.; Delatolla, R.
- 626 Quantitative Analysis of SARS-CoV-2 RNA from Wastewater Solids in
- 627 Communities with Low COVID-19 Incidence and Prevalence. *Water Res.* **2021**,
- 628 *188*, 116560. https://doi.org/10.1016/J.WATRES.2020.116560.

629

630

631

It is made available under a CC-BY-NC 4.0 International license .